Type 2 Innate Lymphoid Cells Protect against Colorectal Cancer Progression and Predict Improved Patient Survival.

Huang, Q; Jacquelot, N; Preaudet, A; Hediyeh-Zadeh, S; Souza-Fonseca-Guimaraes, F; McKenzie, ANJ; Hansbro, PM; Davis, MJ; Mielke, LA; Putoczki, TL; Belz, GT

Type 2 Innate Lymphoid Cells Protect against Colorectal Cancer Progression and Predict Improved Patient Survival.

Huang, Q Jacquelot, N Preaudet, A Hediyeh-Zadeh, S Souza-Fonseca-Guimaraes, F McKenzie, ANJ Hansbro, PM Davis, MJ Mielke, LA Putoczki, TL Belz, GT

Permalink

Publisher:: MDPI AG
Publication Type:: Journal Article
Citation:: Cancers, 2021, 13, (3), pp. 1-16
Issue Date:: 2021-02

In Progress

	Filename	Description	Size
	Type 2 innate lymphoid cells protect against colorectal cancer progression and predict improved patient survival.pdf	Published Version	862.49 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is being processed and is not currently available.

Full metadata record

Field	Value	Language
dc.contributor.author	Huang, Q
dc.contributor.author	Jacquelot, N
dc.contributor.author	Preaudet, A
dc.contributor.author	Hediyeh-Zadeh, S
dc.contributor.author	Souza-Fonseca-Guimaraes, F
dc.contributor.author	McKenzie, ANJ
dc.contributor.author	Hansbro, PM
dc.contributor.author	Davis, MJ
dc.contributor.author	Mielke, LA
dc.contributor.author	Putoczki, TL
dc.contributor.author	Belz, GT
dc.date.accessioned	2021-03-03T04:15:00Z
dc.date.available	2021-01-27
dc.date.available	2021-03-03T04:15:00Z
dc.date.issued	2021-02
dc.identifier.citation	Cancers, 2021, 13, (3), pp. 1-16
dc.identifier.issn	2072-6694
dc.identifier.issn	2072-6694
dc.identifier.uri	http://hdl.handle.net/10453/146697
dc.description.abstract	Chronic inflammation of the gastrointestinal (GI) tract contributes to colorectal cancer (CRC) progression. While the role of adaptive T cells in CRC is now well established, the role of innate immune cells, specifically innate lymphoid cells (ILCs), is not well understood. To define the role of ILCs in CRC we employed complementary heterotopic and chemically-induced CRC mouse models. We discovered that ILCs were abundant in CRC tumours and contributed to anti-tumour immunity. We focused on ILC2 and showed that ILC2-deficient mice developed a higher tumour burden compared with littermate wild-type controls. We generated an ILC2 gene signature and using machine learning models revealed that CRC patients with a high intratumor ILC2 gene signature had a favourable clinical prognosis. Collectively, our results highlight a critical role for ILC2 in CRC, suggesting a potential new avenue to improve clinical outcomes through ILC2-agonist based therapeutic approaches.
dc.format	Electronic
dc.language	eng
dc.publisher	MDPI AG
dc.relation	http://purl.org/au-research/grants/nhmrc/1175134
dc.relation.ispartof	Cancers
dc.relation.isbasedon	10.3390/cancers13030559
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.subject	1112 Oncology and Carcinogenesis
dc.title	Type 2 Innate Lymphoid Cells Protect against Colorectal Cancer Progression and Predict Improved Patient Survival.
dc.type	Journal Article
utslib.citation.volume	13
utslib.location.activity	Switzerland
utslib.for	1112 Oncology and Carcinogenesis
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney
utslib.copyright.status	in_progress	*
dc.date.updated	2021-03-03T04:14:42Z
pubs.issue	3
pubs.publication-status	Published
pubs.volume	13
utslib.citation.issue	3

Abstract:

Chronic inflammation of the gastrointestinal (GI) tract contributes to colorectal cancer (CRC) progression. While the role of adaptive T cells in CRC is now well established, the role of innate immune cells, specifically innate lymphoid cells (ILCs), is not well understood. To define the role of ILCs in CRC we employed complementary heterotopic and chemically-induced CRC mouse models. We discovered that ILCs were abundant in CRC tumours and contributed to anti-tumour immunity. We focused on ILC2 and showed that ILC2-deficient mice developed a higher tumour burden compared with littermate wild-type controls. We generated an ILC2 gene signature and using machine learning models revealed that CRC patients with a high intratumor ILC2 gene signature had a favourable clinical prognosis. Collectively, our results highlight a critical role for ILC2 in CRC, suggesting a potential new avenue to improve clinical outcomes through ILC2-agonist based therapeutic approaches.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/146697